{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:26Z","timestamp":1792112186244,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70876-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:30:48Z","timestamp":1773757848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5863-6240","authenticated-orcid":false,"given":"Xuhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhe","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-2669","authenticated-orcid":false,"given":"Mingzhao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-5475","authenticated-orcid":false,"given":"Hua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7663-9124","authenticated-orcid":false,"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"70876_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-med-062617-035821","volume":"70","author":"RA Clynes","year":"2019","unstructured":"Clynes, R. A. & Desjarlais, J. R. Redirected T cell cytotoxicity in cancer therapy. Annu. Rev. Med 70, 437\u2013450 (2019).","journal-title":"Annu. Rev. Med"},{"key":"70876_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547\u2013562 (2018).","journal-title":"Cancer Cell"},{"key":"70876_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das, M., Zhu, C. & Kuchroo, V. K. Tim-3 and its role in regulating anti-tumor immunity. Immunol. Rev. 276, 97\u2013111 (2017).","journal-title":"Immunol. Rev."},{"key":"70876_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"70876_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","volume":"19","author":"SC Eisenbarth","year":"2019","unstructured":"Eisenbarth, S. C. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19, 89\u2013103 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973\u2013988 (2016).","journal-title":"Immunity"},{"key":"70876_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nri1248","volume":"3","author":"O Acuto","year":"2003","unstructured":"Acuto, O. & Michel, F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939\u2013951 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/eji.1830270136","volume":"27","author":"M Tacke","year":"1997","unstructured":"Tacke, M., Hanke, G., Hanke, T. & Hunig, T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27, 239\u2013247 (1997).","journal-title":"Eur. J. Immunol."},{"key":"70876_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","volume":"3","author":"LH Boise","year":"1995","unstructured":"Boise, L. H. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87\u201398 (1995).","journal-title":"Immunity"},{"key":"70876_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano, A. E. & Anandasabapathy, N. The role of dendritic cells in cancer and anti-tumor immunity. Semin. Immunol. 52, 101481 (2021).","journal-title":"Semin. Immunol."},{"key":"70876_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06890-y","volume":"9","author":"Y Liang","year":"2018","unstructured":"Liang, Y. et al. Targeting IFNalpha to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat. Commun. 9, 4586 (2018).","journal-title":"Nat. Commun."},{"key":"70876_CR15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med"},{"key":"70876_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"70876_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"70876_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer, S., Bannink, M., Van Gool, A. R., Kruit, W. H. & Stoter, G. Side effects of interferon-alpha therapy. Pharm. World Sci. 27, 423\u2013431 (2005).","journal-title":"Pharm. World Sci."},{"key":"70876_CR19","doi-asserted-by":"publisher","unstructured":"Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J. Clin. Invest. 132, https:\/\/doi.org\/10.1172\/JCI153604 (2022).","DOI":"10.1172\/JCI153604"},{"key":"70876_CR20","first-page":"2434","volume":"35","author":"TH Corbett","year":"1975","unstructured":"Corbett, T. H., Griswold, D. P. Jr., Roberts, B. J., Peckham, J. C. & Schabel, F. M. Jr Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35, 2434\u20132439 (1975).","journal-title":"Cancer Res."},{"key":"70876_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41588-020-0636-z","volume":"52","author":"HO Lee","year":"2020","unstructured":"Lee, H. O. et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat. Genet. 52, 594\u2013603 (2020).","journal-title":"Nat. Genet."},{"key":"70876_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 e236 (2019).","journal-title":"Cancer Cell"},{"key":"70876_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol. Life Sci. 79, 191 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"70876_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60463-4","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8(+)T cell exhaustion. Nat. Commun. 16, 5130 (2025).","journal-title":"Nat. Commun."},{"key":"70876_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon, K. O. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595, 101\u2013106 (2021).","journal-title":"Nature"},{"key":"70876_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando, M., Ito, M., Srirat, T., Kondo, T. & Yoshimura, A. Memory T cell, exhaustion, and tumor immunity. Immunol. Med. 43, 1\u20139 (2020).","journal-title":"Immunol. Med."},{"key":"70876_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh, K. & Massague, J. Targeting metastatic cancer. Nat. Med. 27, 34\u201344 (2021).","journal-title":"Nat. Med."},{"key":"70876_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","volume":"25","author":"X Yang","year":"2014","unstructured":"Yang, X. et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37\u201348 (2014).","journal-title":"Cancer Cell"},{"key":"70876_CR29","doi-asserted-by":"publisher","unstructured":"Khalaf, S. et al. Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients. Clin. Immunol. 215, https:\/\/doi.org\/10.1016\/j.clim.2020.108429 (2020).","DOI":"10.1016\/j.clim.2020.108429"},{"key":"70876_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0092-8674(92)90030-G","volume":"68","author":"P Mombaerts","year":"1992","unstructured":"Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869\u2013877 (1992).","journal-title":"Cell"},{"key":"70876_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41551-021-00800-2","volume":"5","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat. Biomed. Eng. 5, 1261\u20131273 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"70876_CR32","doi-asserted-by":"publisher","unstructured":"Xue, D. et al. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Sci. Immunol. 7, https:\/\/doi.org\/10.1126\/sciimmunol.abi6899 (2022).","DOI":"10.1126\/sciimmunol.abi6899"},{"key":"70876_CR33","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","volume":"27","author":"Y Liang","year":"2021","unstructured":"Liang, Y., Hannan, R. & Fu, Y.-X. Type I IFN activating type I dendritic cells for antitumor immunity. Clin. Cancer Res. 27, 3818\u20133824 (2021).","journal-title":"Clin. Cancer Res."},{"key":"70876_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu, W. et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat. Cancer 4, 1309\u20131325 (2023).","journal-title":"Nat. Cancer"},{"key":"70876_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648\u2013659 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"70876_CR38","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41556-022-01024-5","volume":"24","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer. Nat. Cell Biol. 24, 1754\u20131765 (2022).","journal-title":"Nat. Cell Biol."},{"key":"70876_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Huang, D., Saw, P. E. & Song, E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 43, 523\u2013545 (2022).","journal-title":"Trends Immunol."},{"key":"70876_CR40","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","volume":"72","author":"KX Lin","year":"2023","unstructured":"Lin, K. X. et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol. Immunother. 72, 3875\u20133893 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"70876_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh2334","volume":"9","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Sci. Immunol. 9, eadh2334 (2024).","journal-title":"Sci. Immunol."},{"key":"70876_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","volume":"45","author":"M Muhlbauer","year":"2006","unstructured":"Muhlbauer, M. et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J. Hepatol. 45, 520\u2013528 (2006).","journal-title":"J. Hepatol."},{"key":"70876_CR43","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674\u2013687 (2014).","journal-title":"Cancer Discov."},{"key":"70876_CR44","doi-asserted-by":"publisher","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell. Mol. Life Sci. 79, https:\/\/doi.org\/10.1007\/s00018-022-04219-z (2022).","DOI":"10.1007\/s00018-022-04219-z"},{"key":"70876_CR45","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","volume":"20","author":"JM Kirkwood","year":"2002","unstructured":"Kirkwood, J. M. et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20, 3703\u20133718 (2002).","journal-title":"J. Clin. Oncol."},{"key":"70876_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","volume":"25","author":"EI Deryugina","year":"2006","unstructured":"Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9\u201334 (2006).","journal-title":"Cancer Metastasis Rev."},{"key":"70876_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5768-0","volume":"19","author":"E Gobin","year":"2019","unstructured":"Gobin, E. et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic\/prognostic potential. BMC Cancer 19, 581 (2019).","journal-title":"BMC Cancer"},{"key":"70876_CR48","doi-asserted-by":"publisher","unstructured":"Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.aav7431 (2020).","DOI":"10.1126\/scitranslmed.aav7431"},{"key":"70876_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26112-2","volume":"12","author":"X Cao","year":"2021","unstructured":"Cao, X. et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat. Commun. 12, 5866 (2021).","journal-title":"Nat. Commun."},{"key":"70876_CR50","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway, J. B., Presta, L. G. & Carter, P. Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617\u2013621 (1996).","journal-title":"Protein Eng."},{"key":"70876_CR51","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70876-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70876-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:04:17Z","timestamp":1778051057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70876-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70876"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70876-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4081"}}